Equibles does not estimate personal net worth.
Get an email with a short summary when Viridian Therapeutics, Inc.\DE publishes a filing, an earnings call transcript or a press release.
Get VRDN alertsStephen Mahoney is recorded as Board Member and CEO at Viridian Therapeutics, Inc.\DE (VRDN). The newest filing on record that lists Stephen Mahoney as Board Member and CEO at Viridian Therapeutics, Inc.\DE (VRDN) is dated April 17, 2026. Viridian Therapeutics, Inc.\DE reported in an 8-K filed October 30, 2023 that Stephen Mahoney was appointed Class III Director, effective October 30, 2023. Viridian Therapeutics, Inc.\DE reported in an 8-K filed October 30, 2023 that Stephen Mahoney was appointed President and Chief Executive Officer, effective October 30, 2023. The proxy statement of Viridian Therapeutics, Inc.\DE reports total compensation of $6,776,249 for Stephen Mahoney in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 4 fiscal years. Stephen Mahoney has spoken on 1 earnings call across 1 company, most recently for Viridian Therapeutics, Inc.\DE on May 8, 2024. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viridian Therapeutics, Inc.\DE includes Scott Myers (CEO and Board Member), Tomas Kiselak (Chairman), Seth Harmon (CFO) and 7 others.
“Mr. Mahoney was also appointed to the Company's Board of Directors (the "Board") as a Class III Director to serve until the Company's 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.”
“On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company's President and Chief Executive Officer, effective immediately.”
“I'll start by giving a brief overview of Viridian, and then we'll get into more detail about our programs and recent progress.”
Start not stated–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Executive Officer | $700,000 | $6,776,249 |
| 2024 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Executive Officer | $650,000 | $1,117,454 |
| 2023 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Executive Officer | $112,847 | $12,479,521 |
| 2022 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Executive Officer | — | — |
